By contrast, as long as AR is present in prostate cancer, it typically remains an effective target for hormone-directed therapies, even in advanced stages of castration-resistant prostate cancer (CRPC), although increasingly powerful endocrine strategies are needed [186]. This evidence concerns the gene AR and prostate carcinoma.